ARTICLE | Clinical News
FDA approves label expansion for Otonomy's Otiprio
March 16, 2018 4:12 PM UTC
Otonomy Inc. (NASDAQ:OTIC) said FDA approved an sNDA for Otiprio ciprofloxacin to treat acute otitis externa due to Pseudomonas aeruginosa or Staphylococcus aureus infection in patients ages six months and older...
BCIQ Company Profiles